Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Melanoma 22Carcinoma, Renal Cell 19HIV Infections 6Acquired Immunodeficiency Syndrome 6Sarcoma, Kaposi 5Leukemia 5Neoplasm Metastasis 4Lymphoma 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Triple Negative Breast Neoplasms 3Recurrence 3Neoplasms 3Kidney Neoplasms 3Hematologic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Mycosis Fungoides 2Multiple Myeloma 2Leukemia, Myeloid, Chronic-Phase 2Colorectal Neoplasms 2Breast Neoplasms 2Brain Neoplasms 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Tumor Virus Infections 1Thrombocythemia, Essential 1Solid Cancers 1

Interventions

Influenza Vaccines 16trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine 2Vaccines 2Oseltamivir 2FluMist 2Cyclophosphamide 2ziprasidone 1vaxigrip 1thymoglobulin 1peginterferon alfa-2a 1influvac 1fludarabine 1baloxavir 1Zolpidem 1Warfarin 1Vecuronium Bromide 1Vancomycin 1Tranexamic Acid 1Tobramycin 1Starch 1Spironolactone 1Sevelamer 1SARS-CoV-2 inactivated vaccines 1Rocuronium 1Rituximab 1Piperacillin, Tazobactam Drug Combination 1Pentobarbital 1Oxycodone 1Nivolumab 1Nifedipine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Influenza, Human × Interferon alpha-2 × Clear all
NCT00962715 2012-08-03

Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
LymphoidOther hematologic neoplasm

Influenza, Human, Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡